story of the week
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival in Patients With HR+, ERBB2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
JAMA Oncol 2020 Sep 03;[EPub Ahead of Print], SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, G Wulf, L Spring, NF Sinclair, C Andrews, J Pittenger, ET Richardson, D Dillon, NU Lin, B Overmoyer, AH Partridge, E Van Allen, EA Mittendorf, EP Winer, IE KropFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.